cancers Review Mycobiome and Cancer: What Is the Evidence? Natalia Vallianou 1,*, Dimitris Kounatidis 1 , Gerasimos Socrates Christodoulatos 2, Fotis Panagopoulos 1, Irene Karampela 3 and Maria Dalamaga 2,* 1 First Department of Internal Medicine, Evangelismos General Hospital, 45-47 Ipsilantou Str., 10676 Athens, Greece;
[email protected] (D.K.);
[email protected] (F.P.) 2 Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527 Athens, Greece;
[email protected] 3 Second Department of Critical Care, Attikon General University Hospital, Medical School, National and Kapodistrian University of Athens, 1 Rimini St, Haidari, 12462 Athens, Greece;
[email protected] * Correspondence:
[email protected] (N.V.);
[email protected] (M.D.) Simple Summary: Although comprising a much smaller proportion of the human microbiome, the fungal community has gained much more attention lately due to its multiple and yet undiscovered interactions with the human bacteriome and the host. Head and neck cancer carcinoma, colorectal carcinoma, and pancreatic ductal adenocarcinoma have been associated with dissimilarities in the composition of the mycobiome between cases with cancer and non-cancer subjects. In particular, an abundance of Malassezia has been associated with the onset and progression of colorectal carcinoma and pancreatic adenocarcinoma, while the genera Schizophyllum, a member of the oral mycobiome, is suggested to exhibit anti-cancer potential. The use of multi-omics will further assist in establishing whether alterations in the human mycobiome are causal or a consequence of specific types of cancers. Citation: Vallianou, N.; Kounatidis, D.; Christodoulatos, G.S.; Abstract: Background: To date, most researchhas focused on the bacterial composition of the human Panagopoulos, F.; Karampela, I.; microbiota.